Patents by Inventor Elias Lolis

Elias Lolis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and Compositions for Treating Fibrosis
    Publication number: 20230181588
    Abstract: The present invention provides compounds and methods for treating MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Application
    Filed: October 18, 2022
    Publication date: June 15, 2023
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same
    Publication number: 20230146903
    Abstract: The disclosure provides compounds, and compositions comprising such compounds, that can be used to treat CXCR5-expressing cancers, especially angioimmunoblastic T cell lymphoma (AICL) and/or cutaneous T cell lymphoma (CTCL).
    Type: Application
    Filed: March 30, 2021
    Publication date: May 11, 2023
    Inventors: Elias Lolis, Francine Foss, Demetrios Braddock, Yulia Surovtseva, Christopher Fanger, Mark Plummer, Denton Hoyer, Elizabeth Spencer
  • Compounds and compositions for treating fibrosis
    Patent number: 11504373
    Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 22, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • Compounds and Compositions for Treating Fibrosis
    Publication number: 20200390770
    Abstract: The present invention provides compounds and methods for treating, ameliorating, and/or preventing a MKP-5 modulated disease. In certain embodiments, the MKP-5 modulated disease is a fibrotic disease.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 17, 2020
    Inventors: Anton Bennett, Jonathan Ellman, Haya Jamali, Karen S. Anderson, Elias Lolis, Denton Hoyer
  • Identification of allosteric peptide agonists of CXCR4
    Publication number: 20050065064
    Abstract: The chemokine receptor CXCR4 is a co-receptor for T-tropic strains of HIV-1. A number of small molecule antagonists of CXCR4 are in development, but all are likely to lead to adverse effects due to the physiological function of CXCR4. To prevent these complications, allosteric agonists may be therapeutically useful as adjuvant therapy in combination with small molecule antagonists. A synthetic cDNA library coding for 160,000 different SDF-based peptides was screened for CXCR4 agonist activity in a yeast strain expressing functional receptor. Peptides that activated CXCR4 in an autocrine manner induced colony formation. Two peptides, designated RSVM and ASLW, were identified as novel agonists that are insensitive to the CXCR4 antagonist AMD3100. In chemotaxis assays using the acute lymphoblastic leukemia cell line CCRF-CEM, RSVM behaves as a partial agonist and ASLW as a superagonist. The superagonist activity of ASLW may be related to its inability to induce receptor internalization.
    Type: Application
    Filed: August 8, 2003
    Publication date: March 24, 2005
    Inventors: Elias Lolis, Aristidis Sachpatzidis, Henrik Dohlman, John Manfredi